Antimicrobial Drug–Resistant Escherichia coli from Humans and Poultry Products, Minnesota and Wisconsin, 2002–2004
James R. Johnson*† , Mark R. Sannes*†1, Cynthia Croy*†, Brian Johnston*†, Connie Clabots*†, Michael A. Kuskowski*†, Jeff Bender‡, Kirk E. Smith§, Patricia L. Winokur¶#, and Edward A. Belongia**
Author affiliations: *Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA; †University of Minnesota, Minneapolis, Minnesota, USA; ‡University of Minnesota, Saint Paul, Minnesota, USA; §Minnesota Department of Health, Saint Paul, Minnesota, USA; ¶University of Iowa, Iowa City, Iowa, USA; #Iowa City Veterans Affairs Medical Center, Iowa City, Iowa, USA; **Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA;
Figure 2. Distribution of virulence factor scores by source and resistance status among 243 extraintestinal pathogenic Escherichia coli isolates from human feces and poultry products, Minnesota and Wisconsin, 2002–2004. Resistant, resistant to trimethoprim-sulfamethoxazole, nalidixic acid (quinolones), and ceftriaxone or ceftazidime (extended-spectrum cephalosporins). Susceptible, susceptible to all these agents (regardless of other possible resistances). The virulence scores of the susceptible human isolates are an average of ≈4 points greater than those of the resistant human isolates or poultry isolates.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.